Showing results (71-80 of 111) with videos related to
Sort By:
Pageof 12
Lipids|February 1, 1991
Effects of hexadecylphosphocholine on protein kinase C and TPA-induced differentiation of HL60 cellsM Shoji, R L Raynor, E A Fleer, et al.Journal of Lipid Mediators|September 1, 1990
Cytotoxic effects of hexadecylphosphocholine in neoplastic cell lines including drug-resistant sublines in vitroS Danhauser-Riedl, A Himmelmann, G Steinhauser, et al.American Journal of Clinical Oncology|February 1, 1992
Late intensification therapy in adult acute lymphoid leukemia. The Southeastern Cancer Study Group ExperienceO J Martelo, G A Omura, D S Gordon, et al.American Journal of Clinical Pathology|March 1, 1992
Large granular lymphocyte proliferation with the natural killer-cell phenotypeW C Chan, L B Gu, A Masih, et al.Cancer Research|December 1, 1987
Effects of phorbol ester on translocation and down-regulation of protein kinase C and phosphorylation of endogenous proteins in human acute myeloid leukemia cell line KG-1 and its phorbol ester-resistant subline KG-1aM Shoji, P R Girard, P A Charp, et al.Leukemia Research|January 1, 1990
Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trialR S Stein, W R Vogler, E F Winton, et al.Cancer Research|February 1, 1983
Effects of alkyl-lysophospholipids on human leukemic cell lines measured by nuclear magnetic resonanceR C Long, W C Small, R K Brynes, et al.Cancer Research|June 1, 1983
Phospholipid-sensitive Ca2+-dependent protein phosphorylation system in various types of leukemic cells from human patients and in human leukemic cell lines HL60 and K562, and its inhibition by alkyl-lysophospholipidD M Helfman, K C Barnes, J M Kinkade, et al.Leukemia & Lymphoma|February 1, 1995
Establishment and characterization of a new Ph1-positive chronic myeloid leukemia cell line MC3 with trilineage phenotype and an altered p53 geneM Okabe, Y Kunieda, S Nakane, et al.Medical Oncology and Tumor Pharmacotherapy|January 1, 1987
Plasma levels of daunorubicin metabolites and the outcome of ANLL therapyT Gessner, H D Preisler, N Azarnia, et al.Pageof 12